Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Straight Shooter's Corner -- Ignore unavailable to you. Want to Upgrade?

To: waldemar cyranski who wrote (84)	10/9/1999 10:54:00 PM
From: Walter Morton	Respond to of 109

I believe CIST is a can't lose stock at the current price. If they merge the stock price will go up. If they sell pieces of their business they will become more profitable. If they are acquired the stock price will go up. If their research partner takes the option CIST can get $31 million then the stock price will go up. When their new patents are approved the stock price will go up. They recently announced that one of their patents has been used to create a drug that is currently in Phase II clinical trials. Currently CIST is selling for less than its cash and book value per share. CIST has virtually no debt, no preferred shareholders, and no convertible debentures. They also have another $3 million dollars in cash coming in November as a result of the out of court settlement with IMNX. I bought CIST at about $.15 on average.